Price
Financials
Standalone, Rs crore| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Revenue from operations | 135 | 373 | 674 | 965 | 1,067 | 825 | 151 |
| Operating costs | 113 | 315 | 567 | 833 | 860 | 690 | 176 |
| EBITDA | 22 | 58 | 107 | 132 | 207 | 135 | -25 |
| EBITDA margin % | 16% | 16% | 16% | 14% | 19% | 16% | -16% |
| Depreciation & amortisation | 2 | 6 | 8 | 21 | 27 | 61 | 61 |
| Finance costs | 4 | 13 | 25 | 54 | 81 | 121 | 58 |
| Non-operating income | 0 | 0 | 2 | 2 | 20 | -0 | -144 |
| Pre-tax profit | 15 | 39 | 75 | 59 | 120 | -47 | -288 |
| Effective tax rate % | 9% | 17% | 15% | 37% | 28% | 47% | 7% |
| Profit after tax | 14 | 33 | 64 | 37 | 86 | -69 | -307 |
| Earnings per share (Rs) | 31.01 | 50.00 | 19.95 | 44.56 | -35.58 | -158.98 | |
| Paid out as dividend % | 10% | 6% | 4% | 11% | 5% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Revenue CAGR | % | -17% | -46% | -82% | ||
| Profit CAGR | % | % | % | -151% | ||
| Share price CAGR | % | % | % | % | ||
| Average return on equity | % | -4% | -17% | -65% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Net block (property, plant) | 33 | 112 | 204 | 346 | 704 | 1,220 | 1,159 |
| Capital work in progress | 66 | 245 | 331 | 266 | 786 | 285 | 266 |
| Investments | 0 | 0 | 5 | 4 | 0 | 0 | 0 |
| Current & other assets | 58 | 148 | 359 | 519 | 383 | 275 | 103 |
| Total assets | 156 | 505 | 900 | 1,135 | 1,873 | 1,779 | 1,529 |
| Share capital | 10 | 11 | 13 | 19 | 19 | 19 | 19 |
| Reserves & surplus | 19 | 103 | 207 | 253 | 338 | 269 | 219 |
| Total debt | 111 | 352 | 618 | 745 | 950 | 1,157 | 857 |
| Other liabilities & provisions | 16 | 40 | 62 | 118 | 566 | 334 | 434 |
| Equity + liabilities | 156 | 505 | 900 | 1,135 | 1,873 | 1,779 | 1,529 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 8 | 23 | 22 | 42 | 844 | -41 | 3 |
| Investing cash flow | -59 | -188 | -191 | -94 | -938 | -92 | 24 |
| Free cash flow (after capex) | -52 | -165 | -165 | -55 | -61 | -117 | 11 |
| Financing cash flow | 53 | 165 | 226 | 9 | 88 | 130 | -27 |
| Net change in cash | 1 | 0 | 56 | -43 | -6 | -2 | 0 |
| Cash conversion (OCF / EBITDA) % | 38% | 45% | 29% | 36% | 416% | -26% | -18% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Return on capital employed % | 17% | 15% | 12% | 17% | 5% | -7% | |
| Receivable days | 76 | 75 | 89 | 106 | 19 | 17 | 77 |
| Inventory days | 86 | 77 | 83 | 105 | 120 | 98 | 57 |
| Payable days | 19 | 31 | 24 | 28 | 207 | 85 | 478 |
| Cash cycle (days) | 144 | 121 | 148 | 183 | -68 | 29 | -344 |
| Working capital days | 119 | 109 | 134 | 154 | -67 | -14 | -722 |
Fundamentals
Market value₹ Cr.
Last price₹ 3.93
Book value / share₹ 123
Return on capital-6.75 %
Return on equity-65.0 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)-82%
Profit CAGR (TTM)-151%
Standalone figures.
Valuation
P/E, 3-year average4.53x
P/B, 3-year average1.14x
Profitability
Operating margin (excl. other income)13.69%
Operating margin (incl. other income)13.85%
EBITDA margin13.85%
Pre-tax margin6.10%
Net profit margin3.85%
ROE15.12%
ROCE12.19%
ROA3.65%
ROE, 3-year average33.14%
ROCE, 3-year average14.94%
ROA, 3-year average7.53%
ROIC (approx.)7.12%
Tax rate36.98%
Other income / net worth0.57%
Growth
Sales growth (latest year)43.33%
Profit growth (latest year)-41.53%
Sales CAGR, 3 years92.51%
Profit CAGR, 3 years38.49%
Per share
EPS (TTM)Rs 19.95
EPS (latest year)Rs 19.95
EPS, 3-year averageRs 33.65
Book value per shareRs 145.93
Sales per shareRs 518.56
Cash flow per shareRs 22.49
Dividend per share (latest year)Rs 2.25
Dividend per share, 3-year averageRs 2.17
Dividends
Dividend payout11.28%
Dividend payout, 3-year average7.41%
Efficiency
Asset turnover0.85x
Fixed asset turnover2.79x
Inventory turnover3.59x
Inventory days102 days
Debtor days106 days
Debtors turnover3.43x
Leverage
Total debtRs 745 Cr
Cash and bankRs 16 Cr
Net debtRs 729 Cr
Debt to equity2.74x
Net debt / EBITDA5.45x
Interest coverage2.09x
Owners' fund to total sources23.94%
Debt to assets65.64%
Cash flow
Operating cash flow (latest year)Rs 42 Cr
Investing cash flow (latest year)Rs -94 Cr
Financing cash flow (latest year)Rs 9 Cr
Net change in cash (latest year)Rs -43 Cr
Sales to cash flow23.06x
Statement figures
Net sales (TTM)Rs 965 Cr
Net sales (latest year)Rs 965 Cr
Operating profit excl. other income (latest year)Rs 132 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 134 Cr
PBDT (TTM)Rs 80 Cr
Profit before tax (TTM)Rs 59 Cr
Tax (latest year)Rs 22 Cr
Net profit (TTM)Rs 37 Cr
Net profit (latest year)Rs 37 Cr
Depreciation (TTM)Rs 21 Cr
Interest (TTM)Rs 54 Cr
Cost of goods sold (latest year)Rs 763 Cr
Total expenditure (latest year)Rs 833 Cr
Total income (latest year)Rs 967 Cr
Share capitalRs 19 Cr
ReservesRs 253 Cr
Shareholders' fundsRs 272 Cr
Total assetsRs 1,135 Cr
Net blockRs 346 Cr
Capital work in progressRs 266 Cr
InvestmentsRs 4 Cr
ReceivablesRs 281 Cr
InventoryRs 213 Cr
Other liabilitiesRs 118 Cr
Shares outstanding (crore)1.86
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 5 of 7| explain | Receivables outrunning sales Receivables grew 72% vs sales +43% in 2012 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Ankur Drugs & Pharma Ltd?
Ankur Drugs & Pharma Ltd (531683) has a market capitalisation of Rs Cr. at the close.